PABPC1在肝细胞癌患者癌组织中的表达及其与预后的关系

Expression levels of PABPC1 in hepatocellular carcinoma and its relationship with prognosis

目的 分析多聚腺苷酸结合蛋白胞质1(PABPC1)在肝细胞癌(HCC)患者癌组织中的表达情况及其对患者预后的影响。方法 采用癌症基因组图谱计划(TCGA)中的数据分析369例HCC患者癌组织及50例正常肝组织的PABPC1 mRNA表达水平。回顾性分析、比较2018年1月至2019年2月在该院就诊的166例HCC患者癌组织和癌旁正常组织PABPC1 mRNA表达水平及不同临床病理特征的HCC患者癌组织中PABPC蛋白表达情况。绘制受试者工作特征(ROC)曲线分析采用PABPC1 mRNA表达水平区分癌组织和癌旁正常组织的效能,根据随访结果采用多因素COX回归模型分析影响HCC患者预后的因素。结果 TCGA数据结果显示,369例HCC患者癌组织中PABPC1 mRNA表达量显著高于50例正常肝组织中的表达量(P<0.05)。在临床病例分析中,166例HCC患者癌组织中PABPC1 mRNA表达水平及PABPC1蛋白阳性率均显著高于癌旁组织(P<0.05),且PABPC1蛋白阳性表达患者PABPC1 mRNA表达水平为2.76±0.79,显著高于阴性表达患者的1.52±0.84(P<0.001)。ROC曲线结果显示,PABPC1 mRNA区分癌组织和癌旁正常组织的曲线下面积为0.913。UICC分期Ⅲ~Ⅳ期、伴有淋巴结转移以及多发肿瘤灶HCC患者的PABPC1蛋白阳性表达率分别高于UICC分期Ⅰ~Ⅱ期、无淋巴结转移及单发肿瘤灶的患者,差异均有统计学意义(P<0.05)。随访期间,50例(30.12%)患者在术后1年内死亡,95例(57.23%)患者在术后3年内死亡,101例(60.84%)患者在术后5年内死亡;多因素COX回归分析结果显示,癌组织PABPC1蛋白表达情况是影响HCC患者1年、3年、5年生存情况的独立因素(P<0.05)。癌组织PABPC1蛋白阳性表达及阴性表达HCC患者的1年、3年和5年总生存期比较,差异均有统计学意义(P<0.001)。结论 PABPC1 mRNA和蛋白在HCC患者癌组织中均呈高表达,且PABPC1蛋白高表达预示HCC患者生存预后不良。

Objective To analyze the expression of polyadenylate-binding protein 1(PABPC1)in cancer tissues of patients with hepatocellular carcinoma(HCC)and its effect on prognosis.Methods PABPC1 mRNA expression levels in cancer tissues of 369 HCC patients and 50 normal liver tissues were analyzed by data from The Cancer Genome Atlas(TCGA).Retrospective analysis and comparison of PABPC1 mRNA expression levels in cancer tissues and paracancerous normal tissue of 166 HCC patients who attended the hospital from January 2018 to February 2019,and prognosis of HCC patients was conducted,as well as the PABPC1 expression level in cancer tissues of HCC patients with different clinicopathological features.The efficacy of PABPC1 mRNA expression levels to distinguish cancerous tissues from paracancerous tissues was analyzed by plotting receiver operating characteristic(ROC)curve,and factors affecting the prognosis of HCC patients were analyzed by multivariate COX regression analysis auording to the follow-up results.Results The results of TCGA data showed that the PABPC1 mRNA expression level in 369 cancer tissues of HCC patients was significantly higher than that in 50 normal liver tissues(P<0.05).In clinical case analysis,the PABPC1 mRNA and PABPC1 protein positive expression rate in cancer tissues of HCC patients were significantly higher than those in paracancerous tissues(P<0.05),and the PABPC1 mRNA expression level in patients with positive protein expression of PABPC1 was 2.76±0.79,which was significantly higher than 1.52±0.84 in patients with negative expression(P<0.001).ROC curve result showed that the area under the curve of PABPC1 mRNA for distinguishing cancerous tissues from paracancerous tissues was 0.913.The positive expression rates of PABPC1 protein in HCC patients with UICC stageⅢ-Ⅳ,lymph node metastasis and multiple tumor foci were higher than those in HCC patients with UICC stageⅠ-Ⅱ,no lymph node metastasis and single tumor foci,with statistically significant differences(P<0.05).During the follow-up period,50 patients(30.12%)died within 1 year after surgery,95 patients(57.23%)died within 3 years after surgery,and 101 patients(60.84%)died within 5 years after surgery;the results of multivariate COX regression analysis showed that the expression of PABPC1 protein in cancerous tissues was an independent factor influencing the survival of patients with HCC at 1 year,3 years and 5 years(P<0.05).There was a statistically significant difference in 1-year,3-year,and 5-year OS between HCC patients with positive and negative PABPC1 protein expression in cancer tissues(P<0.001).Conclusion The expressions of PABPC1 mRNA and protein are high in cancer tissues of HCC patients,and the high expression of PABPC1 protein predicts poor survival in HCC patients.